AstraZeneca unveils positive results for arthritis treatment study

Biopharmaceutical business AstraZeneca has unveiled positive results from a study of fostamatinib, an oral drug being developed for the treatment of rheumatoid arthritis.

Biopharmaceutical business AstraZeneca has unveiled positive results from a study of fostamatinib, an oral drug being developed for the treatment of rheumatoid arthritis.

In the FTSE 100 company's phase III study, designed to assess the efficacy and safety of fostamatinib, the drug achieved a "statistically significant improvement" in the ACR20 [American College of Rhematology] response rate in patients compared to a placebo.

The ACR score represents the percentage improvement in symptoms in patients, such as tenderness and swelling in the joints.

To qualify for an ACR20, a number of criteria need to be fulfilled. This includes a person with rheumatoid arthritis having at least 20% fewer tender joints and at least 20% fewer swollen joints.

In the study, entitled OSKIRA-1, AstraZeneca said that fostamatinib achieved a "statistically significant improvement in ACR20 response rate at 24 weeks in both the 100 mg twice daily group and the group that received 100 mg twice daily for four weeks followed by 150 mg once daily" when compared to placebo.

The group added that fostamatinib did not demonstrate a statistically significant difference in mTSS [modified Total Sharp Score] compared to placebo at 24 weeks for either dose.

The radiographic modified Total Sharp Score is measured in the hands and feet using X-rays. mTSS is a measure of bone erosion and joint space narrowing on X-rays. A smaller change in mTSS over a given time period, given in percentage change of mTSS score, reflects less progression of joint damage.

AstraZeneca further reported that the safety and tolerability findings for fostamatinib observed in the OSKIRA-1 study were generally consistent with those previously reported for the TASKi Phase II programme.

Briggs Morrison, Managing Director and Executive Vice President of Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "These top-line results provide important information on the efficacy and safety of fostamatinib and demonstrate that the compound has an effect on the signs and symptoms of rheumatoid arthritis.

"We will await the results of the remaining Phase III studies, OSKIRA-2 and OSKIRA-3, to further evaluate and characterise the profile of fostamatinib as a potential treatment for rheumatoid arthritis."

The OSKIRA-2 and OSKIRA-3 results are expected later in the second quarter of 2013.

MF

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

“Joke” cryptocurrency dogecoin goes to the moon. What’s going on?
Bitcoin

“Joke” cryptocurrency dogecoin goes to the moon. What’s going on?

Dogecoin – a cryptocurrency created as a joke – has risen by more than 9,000% this year alone. Saloni Sardana looks at how something that began as an …
19 Apr 2021
The FTSE 100 has clawed back above 7,000 – how much higher can it go?
UK stockmarkets

The FTSE 100 has clawed back above 7,000 – how much higher can it go?

The FTSE 100 index has risen to over 7,000 for the first time in over a year – it now sits just above where it was in 1999. But its era of neglect cou…
19 Apr 2021
The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021